RenovoRx Inc (RNXT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $50.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
RenovoRx Inc (RNXT) Earnings: Report Dates and Results
RenovoRx (RNXT) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, RenovoRx reported EPS of -$0.07, below the -$0.05 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RNXT has an expected report date of Mar 29, 2027.
RNXT Earnings Call
The latest RNXT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, RNXT beat 10, missed 6 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $1.07M, up 302.3% from $266000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.05 | -$0.07 - -$0.03 | -40.00% | Miss | N/A | 2 | 0 up, 0 down | Nov 5, 2026 | $1.07M |
| Jun 30, 2026 | -$0.05 | -$0.08 | -$0.08 - -$0.07 | +37.50% | Beat | N/A | 2 | 0 up, 1 down | Aug 12, 2026 | $909000 |
| Mar 31, 2026 | -$0.08 | -$0.08 | -$0.09 - -$0.07 | 0.00% | In line | N/A | 3 | 2 up, 1 down | May 14, 2026 | $563000 |
| Dec 31, 2025 | -$0.08 | -$0.08 | -$0.08 - -$0.08 | 0.00% | In line | N/A | 3 | 0 up, 1 down | Mar 30, 2026 | $238000 |
| Sep 30, 2025 | -$0.08 | -$0.08 | -$0.08 - -$0.08 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Nov 13, 2025 | $266000 |
| Jun 30, 2025 | -$0.08 | -$0.08 | -$0.08 - -$0.08 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Aug 14, 2025 | $422000 |
| Mar 31, 2025 | -$0.08 | -$0.08 | -$0.08 - -$0.07 | 0.00% | In line | N/A | 2 | 2 up, 0 down | May 15, 2025 | $197000 |
| Dec 31, 2024 | -$0.12 | -$0.13 | -$0.13 - -$0.12 | +4.00% | Beat | N/A | 2 | 0 up, 1 down | Mar 31, 2025 | $43000 |
| Sep 30, 2024 | -$0.10 | -$0.12 | -$0.13 - -$0.11 | +16.67% | Beat | N/A | 3 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.10 | -$0.11 | -$0.11 - -$0.09 | +9.09% | Beat | N/A | 2 | 0 up, 0 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$0.30 | -$0.30 | N/A | 0.00% | In line | N/A | 2 | 1 up, 0 down | Apr 1, 2024 | N/A |
| Dec 31, 2023 | -$0.31 | -$0.30 | -$0.31 - -$0.30 | -3.33% | Miss | N/A | 3 | 0 up, 0 down | Mar 19, 2024 | N/A |
| Sep 30, 2023 | -$0.13 | -$0.28 | N/A | +53.57% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2023 | N/A |
| Jun 30, 2023 | -$0.22 | -$0.29 | N/A | +24.14% | Beat | N/A | 1 | 0 up, 0 down | Aug 16, 2023 | N/A |
| Mar 31, 2023 | -$0.36 | -$0.25 | -$0.25 - -$0.25 | -44.00% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2023 | N/A |
| Dec 31, 2022 | -$0.23 | -$0.26 | -$0.26 - -$0.26 | +11.54% | Beat | N/A | 2 | 0 up, 0 down | Mar 2, 2023 | N/A |
| Sep 30, 2022 | -$0.24 | -$0.29 | -$0.31 - -$0.27 | +17.24% | Beat | N/A | 2 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$0.29 | -$0.28 | N/A | -3.57% | Miss | N/A | N/A | 0 up, 0 down | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$0.33 | -$0.21 | -$0.25 - -$0.17 | -57.14% | Miss | N/A | 2 | 0 up, 0 down | May 16, 2022 | N/A |
| Dec 31, 2021 | -$0.12 | -$0.16 | -$0.18 - -$0.14 | +25.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 30, 2022 | N/A |
| Sep 30, 2021 | -$0.27 | -$0.21 | -$0.29 - -$0.13 | -28.57% | Miss | N/A | 2 | 0 up, 0 down | Nov 15, 2021 | N/A |
| Jun 30, 2021 | -$0.48 | -$0.58 | N/A | +17.24% | Beat | N/A | N/A | N/A | Aug 27, 2021 | N/A |
| Mar 31, 2021 | -$0.57 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | N/A |
| Dec 31, 2020 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | N/A |
| Mar 31, 2020 | -$0.35 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | -$0.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.32, after -$0.62 the year before. It was -$0.48 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.32 | N/A |
| Dec 31, 2024 | -$0.62 | N/A |
| Dec 31, 2023 | -$1.02 | N/A |
| Dec 31, 2022 | -$1.09 | N/A |
| Dec 31, 2021 | -$1.44 | N/A |
| Dec 31, 2020 | -$0.86 | N/A |
| Dec 31, 2019 | -$0.48 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,400 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,431 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,363 | 8 | |
| 2026Q1 | Mar 31, 2026 | 3,793 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,557 | 8 | |
| 2025Q2 | Jun 30, 2025 | 5,991 | 8 | |
| 2025Q1 | Mar 31, 2025 | 2,321 | 6 |
2026Q3 Earnings Call
Opening remarks
Stephanie Carrington Managing Director, ICR Healthcare Thank you, operator. Good afternoon, and welcome, everyone, to the RenovoRx Third Quarter 2026 Earnings Results Conference Call. I am joined today by members of the leadership team, including Shaun Bagai, Chief Executive Officer; Dr. Ramtin Agah, Chief Medical Officer, Executive Chair and Founder; and Mark Voll, Chief Financial Officer. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding RenovoRx's commercial activities and strategies, clinical plans, and expectations of financial or operational performance, including projected revenues, projected active commercial cancer centers, and timing for completion and data readout of the company's TIGeR-PaC trial, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10-Q for the quarter ended September 30, 2026, for detailed discussion of the risks and uncertainties facing RenovoRx. With that, I'd like to turn over the call to our Chief Executive Officer, Shaun Bagai.
Shaun Bagai CEO Thank you, Stephanie, and good afternoon, everyone. The third quarter of 2026 was a milestone quarter for RenovoRx as we continue to deliver on all three of our core priorities. First, for the first time in our history, quarterly revenue exceeded the $1 million threshold. Second, we grew our customer base of active commercial cancer centers, expanded our sales pipeline, and completed the build-out of our sales organization. Third, we advanced the expansion of our TAMP platform and RenovoCath device beyond locally advanced pancreatic cancer. In sum, we continue to deliver on multiple fronts. During the third quarter, RenovoRx generated record revenue of approximately $1.1 million, our strongest quarterly performance to date, increasing approximately 17% sequentially and nearly a 300% increase, or more than 4x higher year-over-year. Revenue for the first 9 months of 2026 was approximately $2.5 million, more than double our full-year 2025 revenue of $1.1 million. This is a direct, measurable result of the commercial model we have described. Every new commercial cancer center we activate drives more procedures and revenue, accelerating growth. Driving much of our growth is our fully staffed sales team, which continues to gain traction and accelerate customer engagement and adoption of TAMP. The sales team, comprised of a Vice President of Sales and Market Development and 5 regional market development managers, is strategically deployed to cover major U.S. cancer centers. Our focused and regionally deployed sales team is sufficiently sized to address the market and effectively penetrate cancer centers that treat solid tumors such as pancreatic cancer.
Frequently Asked Questions About RNXT
When is RenovoRx's next earnings date?
RenovoRx's next earnings report is expected for Mar 29, 2027.
Did RNXT beat earnings estimates last quarter?
No. RenovoRx reported EPS of -$0.07 for the quarter ended Sep 30, 2026, below the -$0.05 estimate by 40.00%.
What EPS do analysts expect from RNXT next quarter?
The consensus EPS estimate for RenovoRx for the quarter ending Dec 31, 2026 is -$0.06 from 6 analysts, with estimates from -$0.07 to -$0.03.
How often does RNXT beat earnings estimates?
RenovoRx beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of +0.19%.
RNXT pages: Overview, Earnings, Forecast, Financials, Competitors